Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk

References

• Prandoni P. Venous and arterial thrombosis: two aspects of the same disease? Eur J Intern Med. 2009;20(6):660–661. doi:10.1016/j.ejim.2009.02.00119782933
   PubMed Web of Science ®Google Scholar
• Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost. 2011;37(8):885–896. doi:10.1055/s-0031-129736722198853
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851–1861. doi:10.1056/NEJMoa090024119329822
   PubMed Web of Science ®Google Scholar
• Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959–1967. doi:10.1056/NEJMoa111423822621626
   PubMed Web of Science ®Google Scholar
• Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979–1987. doi:10.1056/NEJMoa121038423121403
   PubMed Web of Science ®Google Scholar
• Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117(1):93–102. doi:10.1161/CIRCULATIONAHA.107.70920418086925
   PubMed Web of Science ®Google Scholar
• Ribeiro DD, Lijfering WM, Rosendaal FR, Cannegieter SC. Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors. J Thromb Haemost. 2016;14(8):1572–1578. doi:10.1111/jth.1337127214710
   PubMed Web of Science ®Google Scholar
• Zoller B, Li X, Sundquist J, Sundquist K. Socioeconomic and occupational risk factors for venous thromboembolism in Sweden: a nationwide epidemiological study. Thromb Res. 2012;129(5):577–582. doi:10.1016/j.thromres.2011.07.05021868069
   PubMed Web of Science ®Google Scholar
• Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost. 2001;86(1):386–394. doi:10.1055/s-0037-161623611487028
   PubMed Web of Science ®Google Scholar
• Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary-disease - correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92(11):3172–3177.7586300
   PubMed Web of Science ®Google Scholar
• van Schouwenburg IM, Mahmoodi BK, Gansevoort RT, et al. Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study. Thromb Haemost. 2012;108(5):923–929. doi:10.1160/TH12-06-042622955992
   PubMed Web of Science ®Google Scholar
• Morelli VM, Lijfering WM, Bos MHA, Rosendaal FR, Cannegieter SC. Lipid levels and risk of venous thrombosis: results from the MEGA-study. Eur J Epidemiol. 2017. doi:10.1007/s10654-017-0251-1
   Web of Science ®Google Scholar
• Chamberlain AM, Folsom AR, Heckbert SR, Rosamond WD, Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood. 2008;112(7):2675–2680. doi:10.1182/blood-2008-05-15741218614761
   PubMed Web of Science ®Google Scholar
• Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112(6):893–899. doi:10.1161/CIRCULATIONAHA.104.52134416087810
   PubMed Web of Science ®Google Scholar
• Delluc A, Malecot JM, Kerspern H, et al. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism. Atherosclerosis. 2012;220(1):184–188. doi:10.1016/j.atherosclerosis.2011.10.00722035572
   PubMed Web of Science ®Google Scholar
• Everett BM, Glynn RJ, Buring JE, Ridker PM. Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women. J Thromb Haemost. 2009;7(4):588–596. doi:10.1111/j.1538-7836.2009.03302.x19187075
   PubMed Web of Science ®Google Scholar
• von Ballmoos M, Haring B, Sacks FM. The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis. J Clin Lipidol. 2015;9(4):498–510. doi:10.1016/j.jacl.2015.05.00226228667
   PubMed Web of Science ®Google Scholar
• McQueen MJ, Hawken S, Wang XY, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–233. doi:10.1016/S0140-6736(08)61076-418640459
   PubMed Web of Science ®Google Scholar
• Parish S, Peto R, Palmer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J. 2009;30(17):2137–2146. doi:10.1093/eurheartj/ehp22119520708
   PubMed Web of Science ®Google Scholar
• Pechlaner R, Tsimikas S, Yin X, et al. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol. 2017;69(7):789–800. doi:10.1016/j.jacc.2016.11.06528209220
   PubMed Web of Science ®Google Scholar
• Gaudet D, Alexander VJ, Baker BF, et al. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med. 2015;373(5):438–447. doi:10.1056/NEJMoa140028326222559
   PubMed Web of Science ®Google Scholar
• Trenchevska O, Schaab MR, Nelson RW, Nedelkov D. Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. Methods. 2015;81:86–92. doi:10.1016/j.ymeth.2015.02.02025752847
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. Jama. 2005;293(6):715–722. doi:10.1001/jama.293.6.71515701913
   PubMed Web of Science ®Google Scholar
• Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med. 2012;9(1):e1001155. doi:10.1371/journal.pmed.100115522253578
   PubMed Web of Science ®Google Scholar
• Timp JF, Lijfering WM, Flinterman LE, et al. Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study. J Thromb Haemost. 2015;13(10):1823–1832. doi:10.1111/jth.1311326270389
   PubMed Web of Science ®Google Scholar
• van den Broek I, Romijn FP, Nouta J, et al. Automated multiplex LC-MS/MS assay for quantifying serum apolipoproteins A-I, B, C-I, C-II, C-III, and E with qualitative apolipoprotein E phenotyping. Clin Chem. 2016;62(1):188–197. doi:10.1373/clinchem.2015.24670226585923
   PubMed Web of Science ®Google Scholar
• Ruhaak LR, Smit NPM, Romijn F, et al. Robust and accurate 2-year performance of a quantitative mass spectrometry-based apolipoprotein test in a clinical chemistry laboratory. Clin Chem. 2018;64(4):747–749. doi:10.1373/clinchem.2017.28509829378689
   PubMed Web of Science ®Google Scholar
• Thelen MHM, Jansen RTP, Weykamp CW, Steigstra H, Meijer R, Cobbaert CM. Expressing analytical performance from multi-sample evaluation in laboratory EQA. Clin Chem Lab Med. 2017;55(10):1509–1516. doi:10.1515/cclm-2016-097028182577
   PubMed Web of Science ®Google Scholar
• Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood. 2010;116(1):113–121. doi:10.1182/blood-2010-02-26774020385790
   PubMed Web of Science ®Google Scholar
• Ocak G, Vossen CY, Verduijn M, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost. 2013;11(1):116–123. doi:10.1111/jth.1204323106832
   PubMed Web of Science ®Google Scholar
• Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343(7):457–462. doi:10.1056/NEJM20000817343070210950667
   PubMed Web of Science ®Google Scholar
• Kraaijenhagen RA, in’t Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83(1):5–9.10669145
   PubMed Web of Science ®Google Scholar
• Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345(8943):152–155.7823669
   PubMed Web of Science ®Google Scholar
• Rasmussen KL. Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: a review. Atherosclerosis. 2016;255:145–155. doi:10.1016/j.atherosclerosis.2016.10.03728340945
   PubMed Web of Science ®Google Scholar
• Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population. Atherosclerosis. 2016;246:63–70. doi:10.1016/j.atherosclerosis.2015.12.03826761769
   PubMed Web of Science ®Google Scholar
• Mooijaart SP, Berbee JF, van Heemst D, et al. ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med. 2006;3(6):e176. doi:10.1371/journal.pmed.003017616671834
   PubMed Web of Science ®Google Scholar
• Vormittag R, Bencur P, Ay C, et al. Low-density lipoprotein receptor-related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism. J Thromb Haemost. 2007;5(3):497–502. doi:10.1111/j.1538-7836.2006.02337.x17155964
   PubMed Web of Science ®Google Scholar
• Schwarz HP, Lenting PJ, Binder B, et al. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von willebrand factor-deficient mice. Blood. 2000;95(5):1703–1708.10688827
   PubMed Web of Science ®Google Scholar
• Strickland DK, Ranganathan S. Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling. J Thromb Haemost. 2003;1(7):1663–1670.12871303
   PubMed Web of Science ®Google Scholar
• de Sousa JC, Soria C, Ayrault-Jarrier M, et al. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol. 1988;41(9):940–944. doi:10.1136/jcp.41.9.9403056986
   PubMed Web of Science ®Google Scholar
• Moyer MP, Tracy RP, Tracy PB, Veer CV, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol. 1998;18(3):458–465.9514415
   PubMed Web of Science ®Google Scholar
• Winckers K, ten Cate H, Hackeng TM. The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis. Blood Rev. 2013;27(3):119–132. doi:10.1016/j.blre.2013.03.00123631910
   PubMed Web of Science ®Google Scholar
• Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113(5):722–731. doi:10.1161/CIRCULATIONAHA.105.56729716461845
   PubMed Web of Science ®Google Scholar
• White CR, Garber DW, Anantharamaiah GM. Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J Lipid Res. 2014;55(10):2007–2021. doi:10.1194/jlr.R05136725157031
   PubMed Web of Science ®Google Scholar
• Ocak G, Vossen CY, Lijfering WM, et al. Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function. Circulation. 2014;129(6):683–691. doi:10.1161/CIRCULATIONAHA.113.00238524211824
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998;339(1):12–20. doi:10.1056/NEJM1998070233901039647874
   PubMed Web of Science ®Google Scholar
• Hunninghake DB, Stein EA, Dujovne CA, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med. 1993;328(17):1213–1219. doi:10.1056/NEJM1993042932817018464431
   PubMed Web of Science ®Google Scholar